Repligen (RGEN) news
Recent news
Repligen raises FY adjusted EPS to $2.03-$2.09
AInvest Wire · Jul 28, 2026Repligen raises FY26 organic revenue growth guidance to 10.5%-13.5%
Repligen Corp. has raised its full-year 2026 organic revenue growth guidance to a range of 10.5% to 13.5%, reflecting stronger-than-expected performance across its core businesses. The updated guidance comes amid continued demand for its products in the biopharmaceutical and cell and gene therapy…
AInvest Wire · Jul 28, 2026Repligen outlook FY adjusted EPS USD 2.03-2.09
Repligen Corp. (REPX) has provided an updated outlook for fiscal year adjusted earnings per share (EPS), projecting a range of $2.03 to $2.09 [1]. This guidance reflects the company’s current financial performance and strategic direction, incorporating recent operational developments and market…
AInvest Wire · Jul 28, 2026Repligen outlook FY revenue USD 813-835 million
AInvest Wire · Jul 28, 2026Repligen reports second quarter 2026 financial results and updates full year 2026 financial guidance
AInvest Wire · Jul 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.